InDex Pharmaceuticals gets new patent for cobitolimod granted in Europe

Claus Thestrup

Claus Thestrup

CEO, HCA Capital Sweden

InDex Pharmaceuticals has announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office (EPO). The patent provides additional protection for the use of cobitolimod in the treatment of inflammatory bowel disease. The patent, with patent number 3947685, will provide an exclusivity period until August 2040, with the possibility of up to 5 years term extension after market approval.

“We are very pleased that the patent has been granted by the European Patent Office, which again confirms that cobitolimod is a unique and innovative treatment for inflammatory bowel disease,” said Johan Giléus, acting CEO of InDex Pharmaceuticals. “This patent further strengthens, broadens and extends our robust intellectual property position for cobitolimod in Europe.”

Disclaimer: HC Andersen Capital receives payment from Index Pharmaceuticals for a DigitalIR/Corporate Visibility agreement.